Talecris Biotherapeutics

  Home About Talecris Therapeutic Areas Research & Development Donor to Patient Media Center Talecris Careers  
Media Center Overview
Press Releases
News Features
Media Resources
The History of Talecris
Talecris Leadership
Talecris Media Contact Information

The History of Talecris


2006

  Talecris announces the formation of Talecris Plasma Resources and the purchase of its own plasma collection centers
2006   Talecris grants an exclusive worldwide license to Bausch & Lomb for recombinant Plasmin technology for use in ophthalmology
2006   Launch of Talecris Talents, an annual million-dollar grant program to fund basic and clinical research involving use of intravenous immunoglobulin
2006   Talecris expands into Canada and Europe
2005   Talecris receives QSEAL certification from the Plasma Protein Therapeutics Association (PPTA)
2005   Talecris Biotherapeutics established in United States, acquiring the contributed assets of the worldwide plasma business of Bayer BP and the additional fractionation capacity and contract manufacturing services of Precision Pharma Services
 
2004   Bayer BP is first plasma fractionator to receive FDA approval for in-house nucleic acid testing (NAT) of human immunodeficiency virus (HIV)
2003   Launch of Gamunex® (immune globulin intravenous [Human], 10% caprylate / chromatography purified)
2003   Bayer BP uses innovative viral inactivation technology (caprylate) in the production of IGIV
2002   Bayer BP is first company in biological products industry to launch Tamper-Evident-Packaging (TEP)
2001   Western blot assay methodology, the first of its kind in the biological products industry, is developed for testing plasma purification during the manufacture of therapeutic proteins
 
2001   Melville, NY, USA, facility purchased by Ampersand Ventures and renamed Precision Pharma Services
1999   Innovative drug distribution program created (now called Talecris Direct™) for alpha-1 patients; includes services of AlphaNet Coordinators
 
1999   Clayton, NC, USA, facility fractionation capacity reaches 1.9 million liters per year
1995   Miles Inc. renamed Bayer Corporation
1988   Launch of Prolastin® (alpha1- proteinase inhibitor [human]), first proteinase inhibitor product
1981   Approval granted for the first liquid intravenous immune globulin (IGIV), Gamimune® (immune globulin intravenous [human])
1980   Precision Pharma Services predecessor New York Blood Center (Melville Biologics) facility in Melville, NY, USA is licensed by the FDA
1974   Cutter Laboratories completes Clayton, NC, USA facility and begins producing product with a staff of 100 and a capacity of 375,000 liters per year
 
1942 Cutter Laboratories pioneers plasma fractionation and develops first blood product, albumin


Talecris, built on a solid foundation of unparalleled expertise and experience, is now uniquely positioned to create a new standard of excellence in the field of biotherapeutics.

 

 

Print This Page
E-mail This Page
Talecris Biotherapeutics
Contact Talecris    Glossary    Site Map
General Conditions of Use    Privacy Statement    California Compliance
© 2008 Talecris Biotherapeutics